Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases

Leukemia. 2012 Jul;26(7):1693-5. doi: 10.1038/leu.2012.8. Epub 2012 Jan 17.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Benzamides
  • Cells, Cultured
  • Drug Resistance, Neoplasm / drug effects*
  • Humans
  • Imatinib Mesylate
  • Imidazoles / pharmacology*
  • Mice
  • Mutation / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Piperazines / adverse effects*
  • Precursor Cells, B-Lymphoid / cytology
  • Precursor Cells, B-Lymphoid / drug effects*
  • Precursor Cells, B-Lymphoid / metabolism
  • Protein Kinase Inhibitors / adverse effects
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / genetics*
  • Proto-Oncogene Proteins c-kit / genetics*
  • Pyridazines / pharmacology*
  • Pyrimidines / adverse effects*
  • Receptor, Fibroblast Growth Factor, Type 1 / genetics*
  • Receptor, Platelet-Derived Growth Factor alpha / genetics*
  • mRNA Cleavage and Polyadenylation Factors / genetics*

Substances

  • Benzamides
  • Imidazoles
  • Oncogene Proteins, Fusion
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyridazines
  • Pyrimidines
  • mRNA Cleavage and Polyadenylation Factors
  • ponatinib
  • Imatinib Mesylate
  • FGFR1 protein, human
  • FIP1L1-PDGFRA fusion protein, human
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-kit
  • Receptor, Fibroblast Growth Factor, Type 1
  • Receptor, Platelet-Derived Growth Factor alpha